Business Description
Eli Lilly and Co
NAICS : 325412
SIC : 2834
Compare
Compare
Traded in other countries / regions
LLY.USALLY.CanadaLILY34.BrazilLLY.GermanyLLY.ArgentinaLLY.Mexico1LLY.ItalyLLYC.AustriaLLY.SwitzerlandLLYCL.ChileLLY.BulgariaLLYz.UKLLY.France IPO Date
2022-11-14Description
Eli Lilly is a drug firm with a focus on neuroscience, cardiometabolic, cancer, and immunology. Lilly's key products include Verzenio for cancer; Mounjaro, Zepbound, Jardiance, Trulicity, Humalog, and Humulin for cardiometabolic; and Taltz and Olumiant for immunology.
Financial Strength
4/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Cash-To-Debt | 0.12 | |||||
| Equity-to-Asset | 0.19 | |||||
| Debt-to-Equity | 2.13 | |||||
| Debt-to-EBITDA | 2.57 | |||||
| Interest Coverage | 22.56 | |||||
| Piotroski F-Score | 4/9 | |||||
| Altman Z-Score | 10.13 | |||||
| Beneish M-Score | -1.65 | |||||
| WACC vs ROIC | ||||||
Growth Rank
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 3-Year Revenue Growth Rate | 12 | |||||
| 3-Year EBITDA Growth Rate | -1 | |||||
| 3-Year EPS without NRI Growth Rate | 0.8 | |||||
| 3-Year Book Growth Rate | 26.6 | |||||
| Future 3-5Y EPS without NRI Growth Rate | 56.94 | |||||
| Future 3-5Y Total Revenue Growth Rate | 22.68 |
Momentum Rank
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 5-Day RSI | 78.13 | |||||
| 9-Day RSI | 69.48 | |||||
| 14-Day RSI | 64.76 |
Liquidity Ratio
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Current Ratio | 1.11 | |||||
| Quick Ratio | 0.87 | |||||
| Cash Ratio | 0.12 | |||||
| Days Inventory | 273.38 | |||||
| Days Sales Outstanding | 81.94 | |||||
| Days Payable | 125.76 |
Dividend & Buy Back
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Dividend Yield % | 1.11 | |||||
| Dividend Payout Ratio | 0.42 | |||||
| 3-Year Dividend Growth Rate | 15.2 | |||||
| Forward Dividend Yield % | 1.14 | |||||
| 5-Year Yield-on-Cost % | 2.23 | |||||
| 3-Year Average Share Buyback Ratio | 2 | |||||
| Shareholder Yield % | -0.36 |
Profitability Rank
8/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Gross Margin % | 80.75 | |||||
| Operating Margin % | 36.28 | |||||
| Net Margin % | 18.86 | |||||
| FCF Margin % | -9.32 | |||||
| ROE % | 61.77 | |||||
| ROA % | 11.75 | |||||
| ROIC % | 25.06 | |||||
| ROC (Joel Greenblatt) % | 67.68 | |||||
| ROCE % | 24.2 | |||||
| Years of Profitability over Past 10-Year | 9 |
GF Value Rank
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| PE Ratio | 117.33 | |||||
| Forward PE Ratio | 34.18 | |||||
| PE Ratio without NRI | 82.15 | |||||
| Shiller PE Ratio | 170.61 | |||||
| PEG Ratio | 7.68 | |||||
| PS Ratio | 22.1 | |||||
| PB Ratio | 63.25 | |||||
| Price-to-Tangible-Book | 738.47 | |||||
| Price-to-Operating-Cash-Flow | 190.55 | |||||
| EV-to-EBIT | 91.87 | |||||
| EV-to-Forward-EBIT | 52.26 | |||||
| EV-to-EBITDA | 78.67 | |||||
| EV-to-Forward-EBITDA | 46.31 | |||||
| EV-to-Revenue | 22.7 | |||||
| EV-to-Forward-Revenue | 19.19 | |||||
| EV-to-FCF | -243.49 | |||||
| Price-to-Projected-FCF | 16.61 | |||||
| Price-to-Median-PS-Value | 3.84 | |||||
| Price-to-Peter-Lynch-Fair-Value | 10.55 | |||||
| Price-to-Graham-Number | 52.01 | |||||
| Earnings Yield (Greenblatt) % | 1.09 | |||||
| FCF Yield % | -0.42 | |||||
| Forward Rate of Return (Yacktman) % | 8.12 |
Historical Operating Revenue by Business Segment
Historical Operating Revenue by Geographic Region
Guru Trades
See DetailsInsider Trades
See DetailsPeter Lynch Chart
Performance
Dividend
Log
Bar
Annualized Return % Â
Total Annual Return % Â
Eli Lilly and Co Executives
DetailsAnalyst Estimate
Key Statistics
| Name | Value | ||
|---|---|---|---|
| Revenue (TTM) (Mil лв) | 68,469.019 | ||
| EPS (TTM) (лв) | 14.284 | ||
| Beta | 0 | ||
| Volatility % | 0 | ||
| 14-Day RSI | 64.76 | ||
| 14-Day ATR (лв) | 24.486962 | ||
| 20-Day SMA (лв) | 780.925 | ||
| 12-1 Month Momentum % | 0 | ||
| 52-Week Range (лв) | 701.5 - 806 | ||
| Shares Outstanding (Mil) | 900.43 |
Piotroski F-Score Details
Year:
| Component | Result | ||
|---|---|---|---|
| Piotroski F-Score | 4 | ||
| Positive ROA | |||
| Positive CFROA | |||
| Higher ROA yoy | |||
| CFROA > ROA | |||
| Lower Leverage yoy | |||
| Higher Current Ratio yoy | |||
| Less Shares Outstanding yoy | |||
| Higher Gross Margin yoy | |||
| Higher Asset Turnover yoy |
Eli Lilly and Co Filings
| Filing Date | Document Date | Form | ||
|---|---|---|---|---|
| No Filing Data | ||||
Eli Lilly and Co Stock Events
| Event | Date | Price(лв) | ||
|---|---|---|---|---|
| No Event Data | ||||
Eli Lilly and Co Frequently Asked Questions
What is Eli Lilly and Co(XBUL:LLY)'s stock price today?
The current price of XBUL:LLY is лв819.70. The 52 week high of XBUL:LLY is лв806.00 and 52 week low is лв701.50.
When is next earnings date of Eli Lilly and Co(XBUL:LLY)?
The next earnings date of Eli Lilly and Co(XBUL:LLY) is 2024-10-30.
Does Eli Lilly and Co(XBUL:LLY) pay dividends? If so, how much?
The Dividend Yield %  of Eli Lilly and Co(XBUL:LLY) is 1.11% (As of Today), Highest Dividend Payout Ratio of Eli Lilly and Co(XBUL:LLY) was 1.96. The lowest was 0.42. And the median was 0.56. The  Forward Dividend Yield % of Eli Lilly and Co(XBUL:LLY) is 1.14%. For more information regarding to dividend, please check our Dividend Page.
Press Release
| Subject | Date | |||
|---|---|---|---|---|
| No Press Release | ||||
Survey
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
Follow Us
Disclaimers